{"filings":[{"id":1360916,"accession_number":"0001213900-26-073709","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2026-06-30T20:19:25+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Oramed extends Scilex payment obligations; receives $0.5M, $5M due July 31","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Scilex owes ~$29.5M on Tranche A Note and ~$6.7M on Tranche B Note amortization as of June 30, 2026.","Extension agreement: Scilex pays $0.5M (received), $5M by July 31, 2026, balance by Sept 30, 2026.","First $1M received is extension fee; if Scilex fails by Sept 30, first $1.5M becomes non-refundable fee.","If Scilex defaults, remaining obligations may be satisfied via delivery of Scilex common shares.","Bylaws amended to revise record date procedures for stockholder action by written consent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101929,"accession_number":"0001213900-26-037474","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["1.01","2.01"],"status":"ready","headline":"Oramed Pharmaceuticals completes sale of subsidiary Oratech to Lifeward and purchases $9M convertible notes","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Lifeward acquired Oramed's wholly-owned subsidiary Oratech for 1,250,363 ordinary shares, 1,006,113 pre-funded warrants, and share purchase warrants.","Oramed purchased $9,000,000 aggregate principal of Lifeward senior secured convertible notes with initial conversion price of $5.40 per share.","Oramed also received purchase agreement warrants to buy up to 1,666,666 Lifeward ordinary shares at $5.40 per share.","Oramed is entitled to ongoing revenue sharing payments equal to 4% of net revenue from Lifeward's ReWalk exoskeleton products."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101928,"accession_number":"0001012975-26-000195","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2026-02-20T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Oramed receives warrant to buy 100k Scilex shares at $20 in exchange for deferring amortization payment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Oramed deferred its right to receive an amortization payment from Scilex due Oct 1, 2025; payment was made in Nov 2025.","Oramed received a warrant to purchase 100,000 shares of Scilex common stock at $20.00 per share, expiring Dec 13, 2029.","Warrant issued under Section 4(a)(2) and Rule 506(b); Scilex agreed to file resale registration statement.","Beneficial ownership limited to 4.99% (can be raised to 9.99% with 61 days' notice).","Warrant immediately exercisable; exercise price subject to anti-dilution adjustments with floor of $8.22."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101927,"accession_number":"0001213900-26-004382","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2026-01-14T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Oramed to transfer POD platform to Lifeward for 49.9% beneficial ownership; invests $18M in convertible notes","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Oramed to receive up to 49.9% beneficial ownership in Lifeward via shares, pre-funded warrants, plus 4% revenue sharing on ReWalk net sales (max 10 years).","Oramed to invest $9M initial plus $9M milestone-based in 8% senior secured convertible notes convertible at $0.45/sh with 100% warrant coverage.","Lifeward's ReWalk and AlterG products generated $26M revenue in trailing four quarters; CEO Mark Grant has 25+ yrs diabetes experience (Medtronic, BMS).","Transaction requires Lifeward shareholder approval for >19.99% issuance; Oramed to manage clinical trial of oral insulin capsule.","Combines Oramed's oral drug delivery platform with Lifeward's medical robotics; Oramed retains exposure to both platforms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101926,"accession_number":"0001213900-26-001983","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oramed receives $18M payment from Scilex, approves $0.25/share dividend","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$18M payment from Scilex closes Option Agreement; current returns total $118M on $99.5M investment.","Retains $27M note, $12M convertible note ($36/share option), warrants, and nine-year royalty interest.","Board approves $0.25/share cash dividend; payable Jan 26, 2026 to holders of record Jan 16, 2026.","Aggregate dividend ~$10.5M, funded from surplus capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118267,"accession_number":"0001213900-25-127133","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2025-12-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Oramed board member Leonard Sank resigns effective Jan 1, 2026 after 18 years","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Leonard Sank submitted resignation from Board on Dec 31, 2025, effective Jan 1, 2026.","Resignation not due to any disagreement with Oramed on operations, policies, or practices.","Mr. Sank served on the Board for 18 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118266,"accession_number":"0001012975-25-000992","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2025-12-31T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Oramed completes Scilex warrant repurchase; receives $28.5M total","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Scilex repurchased second tranche of 3,370,000 warrants for $14M on Dec 30, 2025.","Oramed also received a $750,000 option fee for the second tranche.","Total aggregate proceeds from both tranches and fees equal $28.5M.","First tranche of 3,130,000 warrants was repurchased for $13M in September 2025.","Subject warrants had an exercise price of $0.01 per share of Scilex common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118265,"accession_number":"0001213900-25-111310","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Oramed reports nine-month 2025 net income of $65M, up from loss of $6.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income (pre-tax) of $65.0M vs. $6.1M loss; basic EPS $1.30, diluted $1.26.","Full $100M repayment from Scilex completed; $27M received in the period.","Total assets up 42% to $220.5M; driven by cash returns and unrealized gains on Alpha Tau (DRTS).","R&D expenses fell to $4.4M from $4.9M; G&A rose to $5.0M from $4.3M.","Unrealized fair-value gains on equity holdings in Alpha Tau and other investments contributed to income."],"consensus_eps_estimate":null,"consensus_eps_actual":1.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":2000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118264,"accession_number":"0001213900-25-111298","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["1.01","3.03","9.01"],"status":"ready","headline":"Oramed adopts poison pill; declares dividend of one Right per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Rights trigger at 15% beneficial ownership; each Right allows purchase of one share at $10.00.","Dividend payable Nov 27, 2025 to holders of record Nov 27, 2025; Rights expire in 3 years.","Board may redeem Rights at $0.012 per Right prior to triggering event; distribution is not taxable.","Rights plan designed to protect against hostile takeovers and ensure fair treatment of shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118263,"accession_number":"0001213900-25-101825","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2025-10-24T23:59:59+00:00","items":["1.01","1.02","2.02","8.01","9.01"],"status":"ready","headline":"Oramed terminates HTIT joint venture, repurchases 1.15M shares, reports ~$210M in assets, launches new insulin trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Repurchased 1,155,367 shares from HTIT Biotech at $2.23/share for $2.58M total; shares cancelled.","Terminated joint venture with HTIT after it failed to satisfy closing conditions; oral insulin program to continue independently.","Preliminary unaudited cash and assets ~$210M as of Sep 30, 2025, up from $155.7M in Jan 2023.","Initiating 60-patient US oral insulin trial targeting high-responder subgroups (lower BMI, older) for >1% HbA1c reduction.","Investment portfolio: $27.1M unrealized gain on Alpha Tau ($64.8M position); Scilex loan returned $95.5M of $99.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118262,"accession_number":"0001213900-25-096322","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Oramed receives $13M from Scilex in first tranche of warrant repurchase","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Scilex repurchased warrants for 3,130,000 shares of Scilex common stock for $13,000,000 on Sept 30, 2025.","Scilex retains option to repurchase remaining 3,370,000 warrants for $14,000,000 by Dec 31, 2025.","Total aggregate purchase price for both tranches is $27,000,000; original option agreement was filed July 23, 2025.","Warrants repurchased have an exercise price of $0.01 per share of Scilex common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134707,"accession_number":"0001213900-25-079361","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2025-08-21T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Oramed shareholders approve 2M-share increase to 2019 stock incentive plan at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to 2019 Stock Incentive Plan, increasing authorized shares by 2M to 9.5M shares.","All seven director nominees re-elected; votes ranged from 12.5M to 13.0M for, with broker non-votes of ~6.4M.","Auditor Kesselman & Kesselman (PwC Israel) ratified for FY2025 with 19.4M for, 1.4M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134706,"accession_number":"0001213900-25-066819","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Oramed grants Scilex option to repurchase Penny Warrants for up to $27M; clarifies warrant terms","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Scilex pays $1.5M option fee in two installments ($750K by Aug 8, 2025; $750K by Dec 16, 2025).","Scilex may repurchase 3.13M warrants for $13M by Sep 30, 2025, and 3.37M warrants for $14M by Dec 31, 2025.","If all payments made, Tranche A Note maturity extends to Mar 31, 2026, and make-whole payment waived.","Oramed clarifies Penny Warrant exercise price remains $0.01/share post 1-for-35 reverse split, not $0.35.","Correction has no impact on financial position, results, or cash flows as of Mar 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151619,"accession_number":"0001213900-25-046436","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Oramed extends $20M stock buyback program through June 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board extended share repurchase program by one year, now expiring June 2026.","Maximum authorization remains $20M; $2.494M in shares repurchased to date.","Repurchases may occur via open market or private transactions; no obligation to buy.","Board may terminate, increase, or decrease authorization at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151618,"accession_number":"0001213900-25-036109","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Oramed invests $36.9M in Alpha Tau, acquires 14.1M shares at $2.612/share","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Oramed subsidiary purchased ~14.1M shares of Alpha Tau (NASDAQ: DRTS) for $36.9M ($2.612/share) via registered direct offering.","Oramed gets right to nominate two directors to Alpha Tau board; board size capped at 8 without Oramed's consent.","Concurrent 3-year IR/PR services agreement; Oramed receives $3M fee plus warrants to buy ~3.24M shares at $3.474-$3.90.","Partnership aims to support Alpha Tau's alpha-radiation cancer therapy Alpha DaRT, including US trials and manufacturing scale-up.","Oramed CEO Nadav Kidron cites alignment in transforming therapeutic delivery; governance role allows strategic influence."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170467,"accession_number":"0001213900-25-019437","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Oramed enters royalty purchase on Gloperba/Elyxyb and rest-of-world license for Gloperba","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Oramed gains right to 50% of 4% net sales royalty on Gloperba and Elyxyb worldwide (effectively 2% of net sales).","Oramed via RoyaltyVest Ltd gets exclusive rest-of-world license for Gloperba; net revenue split 50/50 with Scilex.","Agreements executed Feb 28, 2025 as part of deferral on $50M Scilex convertible notes due Oct 2026.","Oramed transferred 50% of RoyaltyVest shares to other investors; retains right to designate half the board.","Subordination Agreement grants first-priority lien on royalty collateral to Oramed and other purchasers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170466,"accession_number":"0001213900-25-018135","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Oramed's RoyaltyVest signs exclusive Rest of World license for Scilex lidocaine products ZTlido/SP-103","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["RoyaltyVest (50% owned by Oramed) obtains exclusive license to develop, manufacture and commercialize ZTlido (lidocaine 1.8%) and SP-103 outside the U.S.","Revenue share: RoyaltyVest and Scilex Pharma each receive 50% of Net Revenue, paid quarterly by RoyaltyVest.","Licensee must commit $200,000 annually (or in-kind) and obtain regulatory approval in at least one Major Market Country within 18 months of effective date.","Scilex Holding Company guaranteed Scilex Pharma's obligations under the license via a parent guarantee; guarantee terminates upon a change of control.","Oramed transferred 50% of RoyaltyVest shares to Oramed; Oramed controls half of RoyaltyVest's board of directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170465,"accession_number":"0001213900-25-012244","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2025-02-11T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Oramed spins off oral insulin into OraTech JV with HTIT; $75M total investment, Nasdaq IPO planned","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["HTIT to invest $60M, Oramed $15M into OraTech; Oramed shareholders to receive direct stake in new Nasdaq-listed company.","OraTech to launch Phase 3 trial of oral insulin (ORMD-0801) in US this quarter with revised protocol.","HTIT provides supply agreement for oral insulin capsules; OraTech gets global marketing rights to Oramed's POD technology.","OraTech also receives license for oral semaglutide (HT01B) from HTIT for markets outside greater China.","Initial closing deadline extended to April 30, 2025; second closing by May 31, 2025 if Nasdaq listing delayed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170464,"accession_number":"0001213900-25-005212","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2025-01-22T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Oramed extends Scilex note maturity to Dec 2025; receives 3.25M Scilex shares as consideration","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Remaining principal on Tranche A Note is $7.675M; maturity extended from March 21, 2025 to December 31, 2025.","SCLX JV transferred 3,250,000 shares of Scilex common stock to Oramed as consideration for the extension.","Note covenants amended: cash sweep definition updated, and Scilex may not increase officer/director compensation while note outstanding.","Oramed may waive certain prepayments and instead direct prepayment to Tranche B Note holders.","Extension was a condition for payment deferrals under separate Tranche B Note amendments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170463,"accession_number":"0001213900-25-000517","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2025-01-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Oramed defers Scilex $6.25M amortization; receives 2.5M free-trading Scilex shares","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Initial $6.25M amortization due Jan 2, 2025 deferred to Jan 31; further deferral to Oct 2026 conditional on royalty grant.","Oramed receives 2.5M of 5M free-trading Scilex shares from SCLX JV as consideration for the deferral.","Term sheet contemplates 4% royalty on global net sales of Gloperba and Elyxyb (ex-Canada) for 10 years.","Scilex must extend $25M promissory note maturity to Dec 31, 2025; Oramed has discretion on terms.","$1.11M cash paid to noteholders for portion of amortization and make-whole interest."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187452,"accession_number":"0001213900-24-109825","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2024-12-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Oramed recieves $13.2M from Scilex, slashing Tranche A principal to $7.7M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Scilex paid ~$13.2M on Dec 13, 2024, satisfying the $15M installment due Dec 21.","Combined with prior payments, $94.2M of original $101.9M Tranche A Note has been repaid or refinanced.","Remaining Scilex debt to Oramed: $7.675M (Tranche A) and $25M (Tranche B Notes).","Payment stems from September 2023 securities purchase agreement and subsequent October 2024 refinancing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187451,"accession_number":"0001213900-24-091795","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Oramed receives ~$1M prepayment on Scilex Tranche A Note; outstanding reduced to $80.2M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Received ~$1,000,000 mandatory prepayment on Tranche A Note from Scilex on Oct 24, 2024.","After payment, $80,200,000 of original $101.875M principal repaid or refinanced.","Payment represents 70% of net cash proceeds from Scilex debt/equity financings.","Original Tranche A Note issued Sep 2023; $22.5M exchanged for Tranche B Notes in Oct 2024.","$2.5M of principal exchanged for royalty purchase agreement interest."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187450,"accession_number":"0001213900-24-086214","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2024-10-08T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Oramed restructures Scilex debt: exchanges $25M note for convertible notes, warrants, and royalty","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Oramed exchanged $22.5M of its Scilex note for a $25M 5.5% convertible note due 2026 and 3.75M warrants at $1.09.","Oramed exchanged $2.5M of note for a 4.0% royalty on global net sales of ZTlido and SP-103.","Oramed entered binding term sheet for 50% JV with other investors to license lidocaine products outside US, investing $200K/year.","Transactions closed Oct 8, 2024; proceeds repaid $12.5M of Oramed's note and eCapital credit facility.","Scilex issued $50M aggregate convertible notes to Oramed and other investors; Oramed bought $22.5M of that."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203967,"accession_number":"0001213900-24-082237","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2024-09-26T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Oramed signs $11.5M CRO agreement for Phase 3 trial of ORMD-0801 in type 2 diabetes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Oramed Ltd. subsidiary retained InClin as CRO for planned Phase 3 trial of oral insulin candidate ORMD-0801.","Trial to assess safety/efficacy in approximately 300 type 2 diabetes patients under US IND.","Total consideration up to ~$11.5 million, paid monthly based on hours performed over engagement.","Sponsor can terminate with or without cause on 30 days' notice; standard cure period for breach."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203966,"accession_number":"0001213900-24-080812","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2024-09-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oramed & Scilex amend note: $2M prepayment, warrant exercise, liquidity waiver","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Scilex pays Oramed $2M Sept 23: $1.7M to March 2025 amort, $300K buys back 4M $11.50 warrants.","Oramed can immediately exercise CS-5 Warrant for up to 1,062,500 Scilex shares; remaining half exercisable on original date.","Minimum Liquidity covenant under Note reduced to $0 from Sept 19, 2024 until Maturity (March 21, 2025).","$20M amortization payment due Sept 23, 2024 extended to Sept 30, 2024 without default."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203965,"accession_number":"0001213900-24-064732","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2024-08-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Oramed shareholders re-elect all seven directors, approve say-on-pay, ratify auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees re-elected with majority votes; top vote-getter Benjamin Shapiro had 10,120,322 for.","Advisory vote on executive compensation passed: 9,171,779 for, 1,016,334 against.","Ratification of Kesselman & Kesselman (PwC Israel) as FY 2024 auditor approved: 17,323,361 for.","Broker non-votes of 7,236,740 on director elections and say-on-pay due to lack of discretionary voting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220623,"accession_number":"0001213900-24-055950","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Oramed authorizes up to $20M stock buyback program over 12 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized up to $20M in common stock repurchases, expiring in 12 months.","Repurchases may be on open market or private transactions under Rule 10b-18.","Program does not obligate purchase; can be terminated or modified by Board at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220622,"accession_number":"0001213900-24-055006","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Oramed receives $10.4M payment from Scilex on senior secured note; total payments reach $40M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received approximately $10.4M on June 20, 2024, fulfilling the $20M third principal payment obligation under the Scilex note.","Total principal payments received to date stand at $40.0M, up from $29.6M previously.","Note originally issued in September 2023 with principal amount of $101.875M as part of Scilex's assumption of Sorrento obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220621,"accession_number":"0001213900-24-051355","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Oramed Pharmaceuticals appoints Avraham Gabay as CFO effective June 18, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Avraham Gabay appointed CFO, Treasurer, and Secretary, effective June 18, 2024.","Gabay previously served as interim CFO of BiomX Inc. (NYSE American: PHGE) since 2023.","He served as CFO of Oramed from 2019-2021 and as CFO of its 63% subsidiary Oravax Inc. from 2021-2023.","Compensation: gross monthly salary NIS 68,000, company car, eligibility for bonuses and equity at board discretion.","Gabay holds law and accounting degree from Tel-Aviv University, is a CPA in Israel and member of Israeli Bar."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220620,"accession_number":"0001213900-24-041847","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Oramed CFO David Silberman resigns, effective July 12, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Silberman stepped down as CFO, Treasurer and Secretary for personal reasons.","His resignation is effective July 12, 2024, with a transition period until then.","Company has initiated a search for a new CFO to replace Silberman.","The departure is voluntary and not due to any disagreement with Oramed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220619,"accession_number":"0001213900-24-039909","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Oramed receives ~$9.6M prepayment from Scilex on $101.9M note; June 2024 payment reduced to ~$10.4M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received ~$9.6M prepayment on May 2, 2024 from Scilex under mandatory prepayment provision.","Prepayment reduces third installment due June 21, 2024 from $20M to ~$10.4M.","Note originally issued Sep 2023 in principal amount of $101.875M with warrants.","Previously received $20M in principal payments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240246,"accession_number":"0001213900-24-023721","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2024-03-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Oramed receives $15M early payment on Scilex note; $20M due June 21","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received $11.5M on Mar 14 and $3.5M on Mar 18 as early payments toward $15M second principal payment due Mar 21, 2024.","Third principal payment of $20M expected on June 21, 2024.","Note originally $101,875,000 principal, issued Sep 2023 in exchange for Scilex assuming certain Sorrento obligations.","First principal payment of $5M was received Dec 21, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240245,"accession_number":"0001213900-24-023584","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2024-03-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Oramed appoints Yehuda Reznick as director and audit committee chair effective April 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Yehuda Reznick appointed to fill existing board vacancy; also audit committee chair and designated financial expert.","Reznick, 76, was an audit partner at Kesselman & Kesselman (PwC affiliate) from 1999 to 2014.","Compensation same as other non-executive directors; standard indemnification agreement expected.","Currently serves on board of Oravax Medical Inc., an affiliate of Oramed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240244,"accession_number":"0001213900-24-023571","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2024-03-18T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Oramed enters $75M at-the-market equity facility, terminates prior Cantor agreement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM agreement with Rodman & Renshaw and StockBlock Securities for up to $75M of common stock.","Prior Cantor Fitzgerald ATM (up to $100M) terminated March 17, 2024; net proceeds from it were ~$26.25M.","Agents receive 3.0% commission on gross proceeds; Company has no obligation to sell shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240243,"accession_number":"0001213900-24-015108","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2024-02-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oramed plans new U.S. Phase 3 oral insulin trial after subpopulation analysis; JV with HTIT with $70M investment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["HTIT completed Phase 3 for oral insulin in China, in final regulatory approval; JV definitive agreement with $70M from HTIT, $20M from Oramed.","Oramed to initiate new Phase 3 U.S. oral insulin trial later 2024 under differentiated protocol after FDA discussions; earlier Phase 3 missed endpoints.","Scilex issued $101.875M secured note to Oramed at SOFR+8.5%; repayment began Dec 2023; warrants for 13M Scilex shares at $0.01.","Acquired PeriTech film-forming technology for topical/dermatology; entered exclusive licensing deal for royalty on net sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240242,"accession_number":"0001213900-24-005780","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2024-01-23T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Oramed forms JV with HTIT for oral insulin; HTIT contributes $70M, Oramed $20M + IP","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Joint venture will develop oral insulin and POD technology; HTIT contributes $70M cash, Oramed $10M cash + $10M in ORMP shares.","Oramed transfers intellectual property to JV; receives 3% royalty on gross revenues from Oramed-related assets.","JV intends to initiate a Phase 3 oral insulin trial in the United States.","Closing contingent on signing ancillary agreements within 3 months and obtaining IIA approval (estimated redemption fee $2M-$6M).","Initially 50/50 ownership; HTIT has option to invest up to $20M more for increased equity stake."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240241,"accession_number":"0001213900-24-004905","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2024-01-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Yadin Rozov resigns from Oramed board for personal reasons","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Yadin Rozov resigned from the Board of Directors effective January 17, 2024.","Resignation was for personal reasons; no disagreement with company operations, policies or practices.","No replacement or further board changes were announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257753,"accession_number":"0001213900-23-097505","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2023-12-21T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Oramed receives $5M first principal payment on $101.9M Scilex Note; next $15M due March 21, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received $5 million first principal payment on December 21, 2023, under Senior Secured Promissory Note from Scilex.","Next principal payment of $15 million expected on March 21, 2024.","Note principal amount $101,875,000, due 18 months from issuance (September 21, 2023).","Payments are part of Securities Purchase Agreement consummated on September 21, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257752,"accession_number":"0001213900-23-096536","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2023-12-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Oramed appoints Dr. Daniel Aghion to board of directors effective Jan 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board size increased by one; Dr. Aghion fills resulting vacancy effective January 1, 2024.","Aghion is a neurosurgeon at Memorial Neuroscience Institute since 2016.","Compensation will match fees paid to other non-executive directors.","No arrangements or transactions requiring disclosure under Item 404(a) in connection with appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275113,"accession_number":"0001213900-23-079586","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2023-09-26T23:59:59+00:00","items":["1.01","1.02","7.01","9.01"],"status":"ready","headline":"Oramed receives $101.875M senior secured note from Scilex with warrants for 17M shares","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal $101,875,000, 18-month maturity, interest SOFR+8.5% (4% floor), paid in kind.","Oramed gets penny warrants for 13M shares at $0.01 (vesting conditions) and 4M transferred warrants at $11.50.","Note is senior secured on substantially all assets of Scilex and subsidiaries with first-priority lien.","Prior Sorrento SPA and DIP loan terminated; Scilex assumes DIP, buys Sorrento's Scilex equity for $110M.","Oramed receives $2.91M expense reimbursement and right to designate a board observer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275112,"accession_number":"0001213900-23-076238","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2023-09-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oramed restructures Scilex acquisition; enters non-binding term sheets for Securities Transfer by Sept 19","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Scilex declared winning bidder for its own securities from Sorrento; aggregate consideration ~$110M plus ~$12.25M legal fee assumption.","Two paths: Hudson Bay funds $115M (Option 1) or Scilex assumes Oramed's Senior DIP Loan and Oramed gets secured Note (Option 2).","If Option 2, Oramed receives 13M warrants at $0.01/sh and 4M warrants at $11.50/sh in Scilex stock; board observer right.","Closing expected Sept 19, 2023; Bankruptcy Court approved term sheets on Sept 12.","Upon closing, Oramed and Sorrento terminate Stock Purchase Agreement and release all claims."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275111,"accession_number":"0001213900-23-069538","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2023-08-22T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Oramed amends Scilex stock purchase deal; extends deadline, reduces warrants, adds Junior DIP Compromise","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Second Amendment extends Sale Order deadline to Aug 25, 2023; reduces Scilex warrants from ~1.39M to 693K public and from ~3.1M to 1.55M private.","Adds condition that Sale Order must include Junior DIP Compromise, treating Sorrento's recovery identical to general unsecured creditors.","Purchase price remains $105M (credit bid under Replacement DIP Facility and cash). Oramed named successful bidder in auction on Aug 17.","Transaction subject to Bankruptcy Court approval; hearing scheduled Aug 25, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275110,"accession_number":"0001213900-23-064786","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Oramed to acquire Scilex securities from Sorrento for $105M; provides $100M DIP loan","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Oramed will purchase Scilex common and preferred stock plus warrants from Sorrento for $105M total.","Consideration includes a dollar-for-dollar credit bid of outstanding obligations under a $100M replacement DIP facility.","Sorrento is in Chapter 11; transaction subject to Bankruptcy Court approval, auction, and closing by Sept 30, 2023.","Oramed is providing $100M senior secured super-priority DIP loan to Sorrento and Scintilla at 15% interest.","Oramed will receive rights to Scilex Series A preferred stock and governance control via proxy and call option."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275109,"accession_number":"0001213900-23-063876","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oramed signs non-binding term sheet to acquire Scilex securities from Sorrento for $105M; to provide $100M DIP facility","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchase price of $105M for Scilex common (59.7M shares), Series A preferred (29.1M shares), and warrants.","Oramed to provide $100M Replacement DIP Facility to refinance Sorrento's existing $82M DIP; credit bid for purchase.","Option to purchase up to 2,259,058 additional Scilex shares at $1.13 per share within 30 days of transferability.","Stalking horse protections: break-up fee of $3.4125M and expense reimbursement up to $1M if outbid.","Transaction subject to Bankruptcy Court approval, definitive documentation, and possible higher competing bids."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275108,"accession_number":"0001213900-23-056806","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2023-07-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Oramed stockholders re-elect all six director nominees and ratify auditor at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders re-elected Miriam Kidron, Nadav Kidron, Arie Mayer, Yadin Rozov, Leonard Sank, Benjamin Shapiro as directors.","Highest votes for Benjamin Shapiro (9,239,878 for); lowest for Leonard Sank (8,696,513 for); broker non-votes ~7.7M on each.","Ratified Kesselman & Kesselman (PwC) as independent auditor for FY2023 with 16,991,347 for, 50,052 against, 71,751 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292516,"accession_number":"0001213900-23-034728","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2023-05-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Oramed appoints Benjamin Shapiro to Board of Directors effective May 1, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board size increased by one; Benjamin Shapiro appointed to fill vacancy effective May 1, 2023.","Shapiro co-founded The Daily Wire, hosts 'The Ben Shapiro Show', and holds a J.D. from Harvard Law.","Compensation for Shapiro will be the same as for other non-executive directors.","No arrangements or related-party transactions requiring disclosure under Item 404(a) exist."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313169,"accession_number":"0001213900-23-014884","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2023-02-27T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Oramed Pharmaceuticals adopts amended bylaws with new stockholder consent rules and indemnification limits","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board adopted Fourth Amended and Restated By-laws effective February 23, 2023.","New rules for stockholder action by written consent, including record date and independent inspector of election.","Limits indemnification for proceedings commenced by the person unless board-authorized.","Reduces indemnification by amounts collected from other entity for service at another entity.","Requires affirmative vote of majority of outstanding shares to alter, amend, or repeal bylaws."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313168,"accession_number":"0001213900-23-002343","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2023-01-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Oramed Phase 3 oral insulin trial fails; discontinues T2D program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 ORA-D-013-1 of ORMD-0801 missed primary endpoint: mean A1C change at 26 weeks.","Secondary endpoint (fasting plasma glucose) also missed; no serious drug-related adverse events.","Company will discontinue all oral insulin clinical activities for type 2 diabetes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331715,"accession_number":"0001213900-22-078902","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2022-12-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Oramed posts investor presentation; no new material financial or operational data disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed an investor presentation dated December 12, 2022 on its website.","Presentation titled 'Addressing the Multibillion-Dollar Injectable Drug Markets with Oral Formulations' provides a general overview.","No specific financial updates, guidance changes, or pipeline milestones were included in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331714,"accession_number":"0001213900-22-071607","cik":1176309,"company_name":"ORAMED PHARMACEUTICALS INC.","ticker":"ORMP","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Oramed licenses oral insulin (ORMD-0801) to Medicox for South Korea; up to $18M milestones plus 15% royalties","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive 10-year license for ORMD-0801 in South Korea.","Up to $18M in developmental milestones; $2M already received.","Up to 15% royalties on gross sales; Medicox funds regulatory approval.","Medicox also pays transfer price per capsule; distribution targets agreed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":159611723.36683413,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-11-14T23:59:59+00:00|331714"}